0.98 USD
↘ 0.04 (3.74%)AT CLOSE (11:59 AM EDT)
TScan Therapeutics, Inc. Common Stock
TCRXNASDAQ • USD
0.99
↗ 0.00 (0.42%)
POST MARKET (AS OF 07:40 PM EDT)
Post Market
AS OF 07:40 PM EDT
0.99
↗ 0.00 (0.42%)
Market: CLOSED
Open?$1.02
High?$1.03
Low?$0.97
Prev. Close?$1.02
Volume?313.2K
Avg. Volume?634.3K
VWAP?$0.99
Rel. Volume?0.49x
Bid / Ask
Bid?$0.84 × 100
Ask?$1.14 × 100
Spread?$0.30
Midpoint?$0.99
Valuation & Ratios
Market Cap?64.0M
Shares Out?61.1M
Float?42.8M
Float %?81.5%
P/E Ratio?N/A
P/B Ratio?0.66
EPS?-$1.90
Dividend?0.00%
Ex-Dividend?N/A
Shares of TScan Therapeutics, Inc. Common Stock (TCRX) are trading at $0.98. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On valuation, TCRX trades roughly in line with sector averages — neither particularly cheap nor expensive.
Technical & fundamental data as of Jun 5, 2026.
News
Profile
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Themes
Employees
142
Market Cap
64.2M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2021-07-16
Address
830 WINTER STREET
WALTHAM, MA 02451
Phone: 857-399-9500
WALTHAM, MA 02451
Phone: 857-399-9500
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?12
Z-Score?0
Momentum?50
Short Sent.?85
Piotroski F-Score?2/9Weak
Altman Z-Score?-4.72Distress
Confidence?46%Low
Short InterestLow
Short % of Float?2.05%Low
Short Interest?876.6K
Days to Cover?1.0
Free Float42.8M
Avg Daily Volume840.6K
Settlement Date2026-05-15
Financial Health
Current Ratio?6.65Strong
Quick Ratio?6.65Strong
Cash Ratio?6.41Strong
Debt/Equity?0.34Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score83/100
P/E?N/A▾
P/B?0.66CHEAP▾
Peers100
S&P97
P/S?7.01HIGH▾
Peers100
S&P17
P/FCF?N/A▾
EV/EBITDA?0.3CHEAP▾
Peers100
S&P97
EV/Sales?-3.43CHEAP▾
S&P97
Returns & Efficiency
ROE?-128.3%WEAK▾
S&P3
ROA?-61.5%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-124957000
Enterprise Value?$-31359199
Fundamentals ratios updated end of day